Radiochemist
RadioMedix Inc., a Biotechnology Company headquartered in Houston, Texas, is seeking an experienced Radiochemist to work in our Research and Development Team at our corporate office. The successful candidate will play a key role in process development, radioisotope and radiopharmaceutical manufacturing, and life-cycle management of GMP products. This position will focus on high-priority projects at RadioMedix that will be integral to upcoming clinical drug trials. This is a newly created position with potential for significant growth.
We’re a growing company and we continue to add talent from a variety of fields. RadioMedix seeks to hire highly motivated and forward-thinking professionals interested in nuclear medicine research and development and influencing change within the nuclear medicine landscape.
Roles/Deliverables
The Radiochemist will provide technical expertise to support the development of methodologies and procedures for chemical and radiochemical handling, of remote handling systems, and of radiochemical separations. They will also support the development and validation of analytical and radioanalytical methods and procedures that will be used to demonstrate Manufacturing and Quality Control (QC) over radioisotope and radiopharmaceutical production processes. The Radiochemist will support the implementation of Laboratory Information Management Systems (LIMS) and quality assurance procedures under 21 CFR 211, and ICH guidelines.
Research
Production/Manufacturing
Opportunity for growth
Minimum Requirements
Disclaimer
This position is not eligible for employer-sponsored work authorization. Candidates must be authorized to work in the United States on a permanent basis without the need for current or future sponsorship.

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.
RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.